PharmaThing.com

22/01/2024

Bangladesh's economy has been facing tough times of late as sustained high inflation, hike in interest rates and massive devaluation of the local currency continue to plague the country. In this series, we take a look back at how various industries fared amid the crisis in fiscal year 2022-23. Here is the first part on listed pharmaceuticals.

Profits of listed pharmaceutical companies in Bangladesh shrank in the last fiscal year of 2022-23, the first decline in at least five years, as the cost of production went up.

Bangladesh's economy has been facing tough times of late as sustained high inflation, hike in interest rates and massive devaluation of the local currency co...

16/01/2024

The pharmaceutical industry of Bangladesh, an emerging Asian champion of generic drugs, is eyeing Cambodian market owing to its huge growth potential, Bangladeshi media reported.

The pharmaceutical industry of Bangladesh, an emerging Asian champion of generic drugs, is eyeing Cambodian market owing to its huge growth potential, Bangla...

30/12/2021

The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022.

The biotech IPO market has been hot for the past few years, but it set all sorts of new records in 2021. A total of 399 companies priced IPOs in 2021, raising $142.5 billion, according to IPO research firm Renaissance Capital. Those figures made this year the busiest by deal count since 2000, and th...

13/12/2021

https://pharmathing.com/news/nasal-vaccine-may-aid-fight-against-new-viral-variants/

21/04/2021

In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times reported an additional batch of between 10 million and 15 million doses of the AZ vaccine was lost last November because of suspected contamination at the plant.

Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long.

12/04/2021

Pfizer Inc. and BioNTech SE requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age. The companies plan to request similar rulings by other regulatory authorit...

02/04/2021

In the last year, the pharma industry has adapted its approach to meeting new partners and existing customers, with wider pools of suppliers now needed, putting greater pressure on resources to find and evaluate partners before advancing discussions. In response, CPhI Discover will empower the industry with tools to discover and meet new partners remotely, but also, to maximise the value they get from future in person events by helping evaluate more partners in advance and pre-qualify the best leads.

Informa Markets is launching an annual dedicated online platform for pharma in May (17-28th), CPhI Discover – designed to encourage suppliers and customers to source, meet and discover – providing the industry with a new synergistic offering to sit alongside CPhI’s portfolio of in person event...

30/03/2021

COVID-19 prevention measures for those working in GMP pharmaceutical & healthcare facilities
Click: https://pharmathing.com/video/covid-19-prevention-measures-for-those-working-in-gmp-pharmaceutical-healthcare-facilities/

25/03/2021

Producing cell therapies isn’t easy—and that’s a fact Bristol Myers Squibb knows only too well. FDA hang-ups at a viral vector plant delayed CAR-T therapy Breyanzi, sinking a Celgene deal-related payout worth some $6.4 billion.

Producing cell therapies isn’t easy—and that’s a fact Bristol Myers Squibb knows only too well. FDA hang-ups at a viral vector plant delayed CAR-T therapy Breyanzi, sinking a Celgene deal-related payout worth some $6.4 billion.

21/03/2021

Dr. Reddy’s Princeton, New Jersey, outfit is pulling hundreds of thousands of bottles of the cholesterol drug atorvastatin calcium in the U.S. due to impurities that turned up in the product. The company is also recalling one batch of the hormone progesterone after stability testing revealed subpar dissolution.

Dr. Reddy’s Laboratories is in the midst of a large recall of its generic version of Lipitor—and that’s not the only product it’s yanking from the U.S. market.

16/03/2021

The new focused effort in the Rise Above COVID campaign offers masks, hand sanitizers and information cards at barber and beauty shops to direct people how to join a treatment trial if they become infected with COVID-19.

Customers visiting Black-owned barbershops are getting an education along with their undercuts—thanks to a new COVID-19 marketing effort.

09/03/2021

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or were purified antibodies intended for use as drugs, the researchers found more antibody is needed to neutralize the new variants.

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were....